✦ LIBER ✦

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

✍ Scribed by Van Assche, G; Sandborn, W J; Feagan, B G; Salzberg, B A; Silvers, D; Monroe, P S; Pandak, W M; Anderson, F H; Valentine, J F; Wild, G E; Geenen, D J; Sprague, R; Targan, S R; Rutgeerts, P; Vexler, V; Young, D; Shames, R S

Book ID: 125475128
Publisher: BMJ Publishing Group
Year: 2006
Tongue: English
Weight: 1010 KB
Volume: 55
Category: Article
ISSN: 0017-5749
DOI: 10.1136/gut.2005.089854

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

701 A Randomized, Double-Blind, Placebo-

701 A Randomized, Double-Blind, Placebo-Controlled Trial of a Probiotic Preparation, Vsl#3, for the Treatment of Mild to Moderate Active Ulcerative Colitis

✍ Govind K. Makharia; Ajit Sood; Vandana Midha; Vineet Ahuja; Dinesh K. Singal; Re 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 94 KB

A multiple dose randomized double-blind

A multiple dose randomized double-blind placebo-controlled study to determine the efficacy and safety of a humanized anti-CD4 monoclonal antibody in the treatment of moderate to severe chronic psoriasis vulgaris

✍ Gottlieb, AB; Krueger, J; Lebwohl, M; Gisoldi, E; Grossman, RM; Wacholtz, MC 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 190 KB

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled trial of the human anti-TNF-α monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn’s disease

✍ Stephen Hanauer; Milan Lukáš; Donald MacIntosh; Paul Rutgeerts; William Sandborn 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 45 KB

A Multicenter, Randomized, Double-Blind,

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase2b Study of Ustekinumab, a Human Monoclonal Antibody to IL-12/23p40, in Patients With Moderately to Severely Active Crohn's Disease: Results Through Week 22 From the Certifi Trial

✍ William J. Sandborn; Christopher Gasink; Long-Long Gao; Marion Blank; Jewel Joha 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 145 KB

A phase 2 multicenter, randomized, place

A phase 2 multicenter, randomized, placebo- and active-comparator-controlled, dose-ranging trial to evaluate guselkumab for the treatment of patients with moderate to severe plaque-type psoriasis (X-PLORE)

📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 52 KB